No Data
Dabo Healthcare: 2024 Annual Performance Forecast
Double Medical Technology Inc. (002901.SZ): Net income for the year 2024 is expected to increase by 493.50%–561.33%.
Gelonghui reported on January 10 that Double Medical Technology Inc. (002901.SZ) announced its performance forecast for 2024, expecting a Net income attributable to the shareholders of the listed company of 0.35 billion yuan to 0.39 billion yuan, an increase of 493.50% to 561.33% compared to the same period last year; after deducting non-recurring gains and losses, the Net income is expected to be 0.28 billion yuan to 0.32 billion yuan, an increase of 2,552.75% to 2,931.71% year-on-year; the basic EPS is expected to be 0.85 yuan/share to 0.94 yuan/share. With the gradual implementation of orthopedic material procurement policies, the company is actively adjusting its Operation strategy.
The Five-year Shareholder Returns and Company Earnings Persist Lower as Double Medical Technology (SZSE:002901) Stock Falls a Further 4.8% in Past Week
Double Medical Technology Inc. (002901.SZ): has cumulatively repurchased 0.31% of shares.
On January 3, Glonghui announced that Double Medical Technology Inc. (002901.SZ) reported that as of December 31, 2024, the company had repurchased a total of 1,263,000 shares through a dedicated repurchase securities account via centralized bidding, accounting for 0.3051% of the company's total equity, with the highest Fill Price at 35.00 yuan/share, the lowest Fill Price at 31.76 yuan/share, and a total amount of 42.0856 million yuan (excluding trading fees).
Double Medical Technology (SZSE:002901) Seems To Use Debt Quite Sensibly
Double Medical Technology Inc. (002901.SZ): Received a total of 11.9 million yuan in government subsidies.
On December 9th, Gelonghui reported that double medical technology inc. (002901.SZ) announced that the company and its controlling subsidiaries, Shiaid Medical Equipment Co., Ltd. (Xiamen), Baichitai Medical Technology Co., Ltd. (Xiamen), and Saco Medical Technology Co., Ltd. (Xiamen), recently received government subsidies totaling 11.9 million yuan, accounting for 20.18% of the audited net income attributable to shareholders of the listed company in the most recent fiscal year.
Is Double Medical Technology (SZSE:002901) Using Debt Sensibly?
